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Abstract
Background: Pancreatic cancer is a common, highly lethal disease with a rising incidence. MUC1
is a tumor-associated antigen that is over-expressed in pancreatic adenocarcinoma. Active
immunotherapy that targets MUC1 could have great treatment value. Here we investigated the
preventive and therapeutic effect of a MUC1 DNA vaccine on the pancreatic cancer.
Methods: MUC1-various tandem repeat units(VNTR) DNA vaccine was produced by cloning one
repeat of VNTR and inserting the cloned gene into the pcDNA3.1. In the preventive group, female
C57BL/6 mice were immunized with the vaccine, pcDNA3.1 or PBS; and challenged with panc02-
MUC1 or panc02 cell. In the therapeutic group the mice were challenged with panc02-MUC1 or
panc02 cell, and then immunized with the vaccine, pcDNA3.1 or PBS. The tumor size and the
survival time of the animals were compared between these groups.
Results: The DNA vaccine pcDNA3.1-VNTR could raise cytotoxic T lymphocyte (CTL) activity
specific for MUC1. In the preventive experiment, the mice survival time was significantly longer in
the vaccine group than in the control groups (P < 0.05). In the therapeutic experiment, the DNA
vaccine prolonged the survival time of the panc02-MUC1-bearing mice (P < 0.05). In both the
preventive and therapeutic experiments, the tumor size was significantly less in the vaccine group
than in the control groups (P < 0.05). This pcDNA3.1-VNTR vaccine, however, could not prevent
the mice attacked by panc02 cells and had no therapeutic effect on the mice attacked by panc02
cells.
Conclusion: The MUC1 DNA vaccine pcDNA3.1-VNTR could induce a significant MUC1-specific
CTL response; and had both prophylactic and therapeutic effect on panc02-MUC1 tumors. This
vaccine might be used as a new adjuvant strategy against pancreatic cancer.
Background
Pancreatic adenocarcinoma is the fourth leading cause of
cancer death in the world. However recent advances in
diagnostics, staging, and therapy in pancreatic adenocarci-
noma have not resulted in significant improvements in
the long-term survival [1]. Median survival for all patients
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does not exceed 2 years with a 5-year survival rate less than
20% [2]. Therefore new approaches are necessary to
improve the outcome of patients suffering from pancre-
atic cancer.
Immunotherapy has recently become a feasible tumor
specific therapy. MUC1 is a tumor-associated antigen that
is over-expressed in pancreatic adenocarcinomas [3].
MUC1 is a transmembrane molecule whose major extra-
cellular domain is composed of various tandem repeat
units (VNTR) consisting of 20 amino acids (GVTSAP-
DTRPAPGSTAPPAH) and is the most specific epitope for
tumor immunotherapy [4,5]. The MUC1-specific anti-
bodies have been detected in the sera of breast, pancreatic,
and colon carcinoma patients, indicating that MUC1
could induce humoral immune responses [6,7]. Von
Mensdorff-Pouilly et al. reported that breast carcinoma
patients who had natural humoral responses against
MUC1 had a higher probability of disease-free survival
[8]. In addition, MUC1-specific cytotoxic T lymphocytes
(CTLs) have also been found in breast, pancreatic, and
ovarian carcinoma patients [9,10].
Induction of MUC1-specific immune responses has
already been reported in mice and humans. Mice immu-
nized with the MUC1-VNTR peptides [11], MUC1-mann-
nan fusion protein [12], or dendritic cells transfected with
MUC1 cDNA [13] could develop both humoral and cellu-
lar immune responses and suppress the growth of MUC1-
expressing tumors. MUC1 vaccines have also been used in
several clinical trials wherein cancer patients were immu-
nized with either synthetic peptides, or DCs transfected
with MUC1 cDNA. Although MUC1-specific antibodies
and/or CTLs were detected in some patients, they were not
adequate to generate effective anti-tumor immunity
[14,15]. Furthermore, most of the vaccines were used for
prevention of the tumor; and few of them were used for
tumor therapy. Consequently, it is necessary to develop
new vaccination protocols to induce strong anti-tumor
immune responses that are applicable for the therapy of
the pancreatic cancer.
In this paper, we showed that a MUC1 DNA vaccination
strategy succeeded in suppressing pancreatic adenocarci-
noma in C57BL/6 mice.
Methods
Plasmid DNA vaccine construction and manufacturing
The pcDNA3.1-VNTR plasmid encoding a human MUC1
cDNA was constructed as described by Wu [16]. This
MUC1 cDNA encoded 20 amino acids (GVTSAPDTRPA-
PGSTAPPAH), which was one repeat of VNTR. An opti-
mized Kozak sequence and an hMCP-1 sequence were
engineered to the start codon region. Transient transfec-
tion demonstrated that pcDNA3.1-VNTR could induce
expression of human MUC1 in Cos-7 cells.
The pcDNA3-MUC1 plasmid encoding 22 VNTR was
kindly provided by Dr. Finn [17].
Mice and tumor cells
The C57BL/6 mice were bred in the Animal Lab center
(Medical school of Jiaotong University, Shanghai). The
facility was approved by the Association for Assessment
and Accreditation of Laboratory Animal Care Interna-
tional, and all procedures were carried out in accordance
with the Guidelines and Regulations for Use and Care of
Animals in Fudan University. The panc02 is a highly tum-
origenic murine pancreatic tumor cell line with ductal
morphology that was derived in 1984 from a methylcho-
lanthrene-induced tumor growing in a C57BL/6 female
mouse(kindly provided by MD Anderson Cancer
Center)[18]. It produces rapidly growing local tumors
after s.c. inoculation. The MUC1 cDNA (pcDNA3-MUC1)
was transfected into the panc02 cell line using Lipo-
fectamine 2000 Reagent (Invitrogen, Mannheim, Ger-
many) according to the manufacturer's specifications.
After selection with G418, clones that expressed MUC1
(panc02-MUC1-C and panc02-MUC1-F) were obtained
by the limiting dilution method. Control clone panc02-
Neo (abbreviated as panc02) was obtained by panc02
cells transfected with the pcDNA3 vector alone. These cell
lines were maintained in RPMI1640 medium containing
10% heat-inactivated bovine serum (FBS).
Vaccination protocol and tumor challenge studies
Tumor protection
The mice were divided randomly into 3 groups (n = 15).
A total of 100 μg pcDNA3.1-VNTR in 100 μl of PBS was
injected into the anterior tibialis muscle of the mice (every
2 weeks, 3 times). The mice treated with either the empty
plasmid pcDNA3.1 or PBS were used as the control. Seven
days after the third immunization the mice were inocu-
lated with panc02-MUC1 at the interderm of the left ante-
rior leg armpit (1 × 106/each mouse). The tumor
development in individual mice was monitored every 2–
3 days and the tumor size (in mm3) was calculated by the
following formula: 0.5 × length (mm) × width (mm)2.
The survival time (until death or when the tumor volume
was over 1,000 mm3) after the tumor challenge was
recorded.
Tumor therapy
Mice in therapeutic experiments were divided into 4
groups (n = 9), and received s.c. injection of 1 × 106
panc02-MUC1 or panc02 cells in 200 μl of PBS 4 days
before the immunization of pcDNA3.1-VNTR, pcDNA3.1
or PBS. The intramuscular DNA administrations were
repeated on the ninth and thirteenth days after the firstBMC Cancer 2009, 9:191 http://www.biomedcentral.com/1471-2407/9/191
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vaccination. The tumor sizes of the mice were recorded
every 2–3 days to draw a tumor growth curve. The survival
time (until death or when the tumor volume was over
1,000 mm3) after the tumor challenge was recorded to
evaluate the therapeutic effect of the DNA vaccine.
Cytotoxicity assay
Cytotoxicity of CTL against the target cells was detected by
a non-radioactive lactate dehydrogenase (LDH)-releasing
assay (CytoTox96, Promega, USA). Mice were vaccinated
with pcDNA3.1-VNTR, pcDNA3.1 plasmids (100 μg each
plasmid) or PBS three times at biweekly intervals. Spleno-
cytes were harvested 7 days after the third immunization.
Then the splenocytes were isolated and samples were
pooled and resuspended in RPMI complete media (RPMI
1640, 100 U/ml penicillin, 100 μg/ml streptomycin,
10%FBS). The effector cells were added to the target cells
(panc02-MUC1 or panc02) in a 96-well plate at effector:
target (E: T) ratios of 80:1, 40:1, 10:1. The procedure was
carried out according to the manufacturer's instructions.
Cytotoxicity was calculated using the following formula:
Where E: the experimental LDH release in effector plus
target cell co-cultures; Se: the spontaneous release by
effector cells alone; St: the spontaneous release by target
cells alone; Mt: the maximal release by target cells.
Anti -MUC1 antibody
Serum samples were obtained from mice via retro-orbital
bleeding 5 days after the third vaccination. Samples were
analyzed for the presence of anti-MUC1 antibodies by
ELISA. Microtiter plates were coated with 50 ng/well
MUC1 protein (VNTR) at 4°C overnight. The plates were
blocked (0.5% porcine gelatin, 4% BSA in PBS) and serum
samples were assayed at 1:200 dilution. Anti-MUC1 anti-
bodies were detected with horseradish peroxidase (HRP)-
labeled anti-mouse IgG and developed with tetramethyl-
benzidine-stable. Absorbance was read at 450 nm. 1/titer
values were scored as positive for the presence of MUC1
antibodies if the OD readings were at least three-times
over PBS control wells.
Statistical analysis
Data are presented as mean ± S.E.M. Statistical differences
between two groups were evaluated by the unpaired Stu-
dent's t-test. One-way ANOVA was used for the compari-
sons among three groups. The survival time was
calculated by the Kaplan-Meier method. The survival rates
were compared by the log-rank test (SPSS v11.0). P-values
less than 0.05 were considered significant.
Results
Monoclonal cell line verifications
Western blot analysis
The monoclonal cell line panc02-MUC1-C and panc02-
MUC1-F could express the MUC1 protein while the con-
trol cell line panc02-Neo showed no expression of the
MUC1 (Figure 1). The cell line panc02-MUC1-C was
named pan02-MUC1 and used in subsequent experi-
ments, while the cell line transfected with pcDNA3 was
named panc02-Neo (abbreviated as panc02).
Immunostaining
MUC1 was expressed in the monoclonal cell line panc02-
MUC1, especially on the surface of the cells, however the
panc02 cell line showed no expression of MUC1 (Figure
2).
Protective immune response
To study the protective immune response of pcDNA3.1-
VNTR vaccine against pancreatic cancer, the mice were
inoculated with pcDNA3.1-VNTR three times before the
mice were challenged with 1 × 106panc02-MUC1 or
panc02. As shown in Figure 3A, vaccination with
pcDNA3.1-VNTR resulted in a significant protection com-
pared to the empty vector and PBS (P < 0.0001 by one-
way ANOVA). Furthermore, the protection against the
tumor was MUC1-specific, since the mice that were
immunized with pcDNA3.1-VNTR, followed by challeng-
ing with panc02 tumor cells were not protected (Figure
3B, P < 0.0001 by t-test). These results demonstrated that
the pcDNA3.1-VNTR vaccine could induce MUC1-specific
tumor protection.
Long-term survival of pcDNA3.1-VNTR-vaccinated mice
was assessed. Immunized mice were tumor-challenged
and monitored for tumor growth until death or until the
tumor volume was over 1000 mm3. As show in Figure 4A,
the mice immunized with pcDNA3.1-VNTR were pro-
tected better against the panc02-MUC1 tumor cells than
the mice in the pcDNA3.1 and PBS groups, because the
mice in this group survived longer in comparison with the
Cytotoxicity E Se St Mt St (%) [( )/( )] % =− − −× 100
Monoclonal cell line western blot analysis Figure 1
Monoclonal cell line western blot analysis. Panc02-
MUC1-C and panc02-MUC1-F were transfected with 
pcDNA3-MUC1; while panc02-Neo was transfected with 
pcDNA3. The cell line panc02-MUC1-C and panc02-MUC1-F 
expressed the MUC1 protein.BMC Cancer 2009, 9:191 http://www.biomedcentral.com/1471-2407/9/191
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mice in the other two groups. Moreover this effective pro-
tection was MUC1-specific, because the survival time of
the mice immunized with pcDNA3.1-VNTR and chal-
lenged with panc02 tumor cells did not increase (Figure
4B).
Anti -MUC1 antibody
Because specific antibodies also play a role in antitumor
immunity, we measured the anti-MUC1 titres in the
serum of immunized mice by ELISA, 5 days after the third
time immunization. As shown in Figure 5, relatively
higher titres of anti-MUC1 antibodies were detected in the
serum of pcDNA3.1-VNTR-vaccinated mice than the
empty vector and PBS vaccinated groups (P < 0.05 by one-
way ANOVA)
Induction of Cytotoxicity responses
To determine whether immunization with pcDNA3.1-
VNTR could induce strong CTL responses in mice, we car-
ried out the nonradioactive LDH-releasing assay (Figure
6). To measure the specific cytotoxicity, splenocytes from
immunized mice were isolated 7 days after the third
immunization, and then co-cultured with panc02-MUC1
or panc02 cells at various E/T rations. Splenocytes from
mice immunized with pcDNA3.1-VNTR could kill
panc02-MUC1, but not panc02, much more efficiently
than those from the mice immunized with empty vector
or PBS. As shown in Figure 6, when the ratio of E:T was
80:1, effector cells of the pcDNA3.1-VNTR immunized
group showed a cytotoxicity of 56.84 ± 3.54% against
panc02-MUC1 cells, and when this ratio was 40:1, the
cytotoxicity was 39.71 ± 1.97%. This cytotoxicity activity
could be inhibited by the anti-MUC1 antibody VU3C6
(Chemicon). However these effector cells had no cytotox-
icity activity against the panc02 cells. These results con-
firmed the superior ability of pcDNA3.1-VNTR to induce
MUC1-specific CTL compared to the other groups.
Therapeutic antitumor immunity
In the therapeutic study, administration of the DNA vac-
cine started 4 days after the mice injected with a tumori-
genic dose of panc02-MUC1 or panc02 cells and were
repeated on day 9 and day 13. As shown in Figure 7A,
panc02-MUC1 tumor growth on day 25 was inhibited
more significantly in the mice immunized with
pcDNA3.1-VNTR than in the mice immunized with
pcDNA3.1 or PBS (P  < 0.05). In contrast, the panc02
tumor growth was not inhibited in mice treated with the
pcDNA3.1-VNTR, compared with the mice inoculated
with panc02-MUC1 cells as shown in the Figure 7B (P <
0.05). Furthermore most of the mice inoculated with
panc02 died before day 25.
The panc02-MUC1 tumor bearing mice immunized with
pcDNA3.1-VNTR survived longer than the mice in the
control groups (Figure 8A, P < 0.05). However mice inoc-
ulated with panc02, and immunized with pcDNA3.1-
VNTR had developed lethal tumors and died within 15
days, while the mice inoculated panc02-MUC1 had a
longer survive time (Figure 8B, P < 0.05). These results
demonstrated the inhibitory effect of pcDNA3.1-VNTR
vaccine on tumor growth in vivo and indicated that the
anti-tumor activity induced by the pcDNA3.1-VNTR was
specific for MUC1-expressing tumor cells.
Discussion
Despite advances in the understanding of pancreatic can-
cer molecular biology, systemic treatment of this disease
remains unsatisfactory. Conventional chemotherapy and
radiotherapy have not produced dramatic improvements
in response rates or patient survival. Therefore new treat-
ment strategies are clearly needed for this disease.
In 1992, Jonston et al first reported the immunization
strategy using the naked DNA vaccine [19]. The injection
of naked plasmid DNA into the muscle results in gene
expression, which, in return, induces cellular and
humoral immune responses against the expressed pro-
tein. Compared to the conventional immunization strat-
egy, the DNA vaccine might provide several important
advantages. 1) DNA vaccines could induce MHC-
|restricted CD8+ T cell response, which may be advanta-
geous compared with conventional protein vaccines.2)
DNA vaccines could be manufactured in a relatively less
cost manner and stored in relative easy way. 3) DNA vac-
cines could induce cellular and humoral immunity [20].
Although the DNA vaccination approach seems safe and
promising, DNA vaccination with oncogenes still harbors
the risk of transformation for the cells that receive and
express the oncogenes. MUC1 is a tumor-associated anti-
gen that is over-expressed in pancreatic adenocarcinomas.
Although the tumor-associated antigen MUCl could be a
potential target molecule for a protective immune
Monoclonal cell line Immunostaining analysis Figure 2
Monoclonal cell line Immunostaining analysis. Panc02-
MUC1 could express MUC1 proteins especially on the mem-
brane; panc02-Neo had no expression of MUC1.BMC Cancer 2009, 9:191 http://www.biomedcentral.com/1471-2407/9/191
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Tumor protection in mice immunized with pcDNA3.1-VNTR Figure 3
Tumor protection in mice immunized with pcDNA3.1-VNTR. A:Mice were immunized with either pcDNA3.1-VNTR, 
or the empty vector pcDNA3.1, or PBS, as indicated in the legends, followed by challenge with panc02-MUC1 tumor cells (n = 
15 mice/group). Each plasmid was administrated at 100 μg doses. The mean tumor volume of the mice immunized with 
pcDNA3.1-VNTR was significantly smaller than that in the mice in the other two groups (PBS and pcDNA3.1) (mean ± S.E.M. 
P < 0.0001). B: Mice were immunized with pcDNA3.1-VNTR, and then challenge with panc02 tumor cells (n = 6). The mean 
tumor volume in these mice was significantly different from that in mice immunized with pcDNA3.1-VNTR and challenged with 
panc02-MUC1 (mean ± S.E.M. P < 0.0001).
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Effect of DNA vaccine on survival of tumor challenged mice Figure 4
Effect of DNA vaccine on survival of tumor challenged mice. A: Mice were immunized with pcDNA3.1-VNTR, the 
empty vector pcDNA3.1, or PBS, as indicated in the legends, followed by challenge with panc02-MUC1 tumor cells. Mice were 
monitored for tumor development until a tumor volume of over 1000 mm3 or death. As shown in the figure, the mice immu-
nized with pcDNA3.1-VNTR survived longer compared to the mice in the other two groups (P < 0.05 by Log-rank test). B: 
Mice immunized with pcDNA3.1-VNTR, followed by challenge with panc02 tumor cells had a much shorter survival time com-
pared with the mice challenged with panc02-MUC1(P < 0.05 by Log-rank test).
 
0 10 20 30
0
100
 
20
40
60
pcDNA3.1-VNTR
80
days after tumor chanllenge
p
e
n
t
 
s
u
r
v
i
v
a
l
(
%
)
A
PBS
pcDNA3.1
e
r
c
0 5 10 15 20 25 30
0
20
40
60
80
100 pcDNA3.1-VNTR-panc02-MUC1
pcDNA3.1-VNTR-panc02
days after tumor chanllenge
p
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
(
%
)
B
 BMC Cancer 2009, 9:191 http://www.biomedcentral.com/1471-2407/9/191
Page 7 of 11
(page number not for citation purposes)
response against MUC1-expressing carcinoma cells,
tumors are not normally rejected by the host's immune
system, despite the fact that MUC1-specific CTLs have
been detected in cancer patients. Therefore it is necessary
to adjust the MUC1 vaccine to enhance the humoral and
cellular immunity.
To investigate the protective and therapeutic effect of the
DNA vaccine pcDNA3.1-VNTR against pancreatic cancer,
we first constructed a murine pancreatic cancer cell which
could express the human MUC1 protein and mainly on
the cell membrane (Figure 1 and Figure 2). Although
human MUC1 is homologous to murine MUC1, it is still
a foreign protein and might induce an immune response
from the host itself. In the preventive and therapeutic
experiments, however, the differences between
pcDNA3.1-VNTR, pcDNA3.1 and PBS groups challenged
with panc02-MUC1 are large, as discussed below.
Compared to other MUC1 DNA vaccine, our vaccine
pcDNA3.1-VNTR had two specific traits. 1) The optimized
Kozak and hMCP-1 sequences were engineered to the start
codon region which could enhance the expression of
VNTR in muscle cells, thereby inducing more specific
CTLs. 2) The vaccine only had one VNTR repeat that could
make it much more specific and reduce the passive effect
from the other MUC1 sequences [16]. After the injection
of pcDNA3.1-VNTR in muscle, there are at least three
mechanisms by which the antigen encoded by plasmid
DNA is processed and presented to elicit an immune
response: 1) direct priming by somatic cells (myocytes,
keratinocytes or any MHC-||negative cells); 2) direct
transfection of professional antigen presenting cells
(APCs); and 3) cross-priming in which plasmid DNA
transfects a somatic cells and/or professional APCs and
the secreted protein is taken up by other professional
APCs and presented to T cells [20]. Our observations indi-
cated that three intramuscular injections of pcDNA3.1-
VNTR suppressed, in a MUC1-specific manner, the devel-
opment of pancreatic cancer expressing MUC1 in C57BL/
6 mice (Figure 3). The mice immunized with pcDNA3.1-
VNTR followed with the challenge of panc02-MUC1 had
a much longer life span than the mice in the control
groups (P < 0.05, Figure 4). The MUC1 immunotherapy
literatures indicate that cellular immune responses are
required for tumor protection. Our cytotoxicity assay
showed that splenocytes from the pcDNA3.1-VNTR-
immunized mice could specifically kill the panc02-MUC1
tumor cells, but not the panc02 tumor cells, and this cyto-
toxicity could be specifically inhibited by the MUC1 mon-
oclonal antibody VU3C6 (Figure 6). Many studies have
shown that the antibody responses to MUC1 play little
role in tumor protection, if any [21]. In our experiments,
however, anti-MUC1 antibody responses were much
higher in the pcDNA3.1-VNTR vaccinated mice, and this
may play an important role in mediating tumor protec-
tion (Figure 5).
Theoretically, any kind of vaccine should be able to erad-
icate the tumor. Few studies, however, demonstrated the
effect of the MUC1 DNA vaccine on the therapy of pancre-
atic cancer, and most studies have focused on the preven-
tive effect of the DNA vaccine [22,23]. Gabriele et al [24]
conducted a phase I/II clinical trial using human autolo-
gous DC transfected with cDNA of the human tumor anti-
gen MUC1 as a vaccine in 10 patients with advanced
breast, pancreatic or papillary cancer. Their results showed
that immunologic responses could be induced even in
patients with advanced disease; yet, long time survival
could not be achieved. Ramesh K et al [25] conducted
another phase I study of a MUC1 vaccine composed of
different doses of MUC1 peptide with SB-AS2 adjuvant in
resected and locally advanced pancreatic cancer. Two of
15 resected pancreatic cancer patients achieved disease
Induction of specific antibody responses Figure 5
Induction of specific antibody responses. Mice were 
immunized with pcDNA3.1-VNTR, pcDNA3.1 or PBS and 
sera were harvested 5 days after the third immunization. The 
MUC1-specific IgG antibodies in sera of different groups 
were determined at a 1:200 dilution by ELISA. As shown in 
figure, relatively higher titres of anti-MUC1 antibodies were 
detected in the serum of pcDNA3.1-VNTR-vaccinated mice 
compared to that in the sera of the empty vector and PBS 
vaccinated groups (P < 0.05 by one-way ANOVA). 
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free for 32 and 61 months at follow-up. Their results
showed that MUC1 100 mer peptide with SB-AS2 adju-
vant was a safe vaccine that could induce low but detecta-
ble mucin-specific humoral and T-cell responses in some
patients.
Our study was the first to use the pcDNA3.1-VNTR vac-
cine, which had a significant therapeutic effect on pancre-
atic cancer. On day 0 the mice in therapy experiments
were inoculated with 1 × 106 panc02-MUC1 or panc02
cells. Considering that the pancreatic cancer is a very
lethal disease and panc02 cells could easily develop
tumors in the C57BL/6 mice, the therapeutic immuniza-
tion was performed 4 days after the inoculation and the
mice were immunized 3 times. As shown in the Figure 7A,
the panc02-MUC1 tumor volume in the mice immunized
with pcDNA3.1-VNTR was much smaller than the mice
immunized with pcDNA3.1 or PBS (P < 0.05) and the
panc02 tumor growth was not inhibited by the immuni-
zation with pcDNA3.1-VNTR (Figure 7B, P < 0.05). Most
of the mice inoculated with panc02 cells died before
day25. Survival analysis showed that the panc02-MUC1
tumor bearing mice immunized with pcDNA3.1-VNTR
had a longer survival than the control groups (Figure 8A,
P < 0.05). However mice inoculated with panc02, and
immunized with pcDNA3.1-VNTR developed lethal
tumors and died within 15 days, while the mice inocu-
lated with panc02-MUC1 survived longer(Figure 8B, P <
0.05). These results showed that the pcDNA3.1-VNTR vac-
cine had a specific therapeutic effect on tumor growth in
vivo, and the anti-tumor activity induced by the
pcDNA3.1-VNTR was MUC1-specific.
Conclusion
We constructed a useful MUC1 DNA vaccine. The vaccine
was successful in the prevention of tumor establishment
and treatment of established tumors in our model. Our
data suggested that similar immunization strategies might
be used in pancreatic cancer patients with over-expression
of MUC1 for the treatment of early cancers or the eradica-
tion of minimal residual lesions. Further research is
needed to increase the effectiveness of this vaccine.
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Induction of cytotoxicity responses Figure 6
Induction of cytotoxicity responses. Splenocytes from immunized mice were isolated 7 days after the third immunization. 
CTLs were from mice immunized with pcDNA3.1-VNTR, pcDNA3.1 or PBS. Panc02-MUC1or panc02 cells were used as tar-
gets. The CTLs induced by the pcDNA3.1-VNTR could specifically kill the panc02-MUC1 cells, but not the panc02 cells and it 
could be blocked by anti-MUC1 antibody VU3C6.
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Induction of therapeutic anti-tumor immunity Figure 7
Induction of therapeutic anti-tumor immunity. A: Panc02-MUC1 tumor growth on day 25 was inhibited significantly in 
mice immunized with pcDNA3.1-VNTR compared to that in the mice immunized with pcDNA3.1 or PBS (P < 0.05). B:The 
panc02 tumor growth was not inhibited in mice treated with the pcDNA3.1-VNTR.
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Effect of DNA vaccine therapy on survival of tumor-bearing mice Figure 8
Effect of DNA vaccine therapy on survival of tumor-bearing mice. A: The panc02-MUC1 tumor bearing mice immu-
nized with panc02-VNTR had a longer survive time than the pcDNA3.1 and PBS groups(P < 0.05). B: Mice inoculated with 
panc02 and immunized with pcDNA3.1-VNTR developed lethal tumors and died within 15 days, while the mice inoculated 
panc02-MUC1 had a longer survive time(P < 0.05).
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